- Report
- December 2025
- 150 Pages
Global
From €5285EUR$5,950USD£4,605GBP
- Report
- January 2026
- 192 Pages
Global
From €3149EUR$3,545USD£2,743GBP
€3499EUR$3,939USD£3,048GBP
- Report
- February 2026
- 250 Pages
Global
From €3988EUR$4,490USD£3,475GBP
- Report
- May 2026
- 483 Pages
Global
From €5196EUR$5,850USD£4,527GBP
- Report
- October 2025
- 160 Pages
Global
From €2982EUR$3,358USD£2,598GBP
€3509EUR$3,950USD£3,057GBP
- Clinical Trials
- April 2026
- 180 Pages
Global
From €1777EUR$2,000USD£1,548GBP
- Report
- June 2025
- 150 Pages
India
From €5285EUR$5,950USD£4,605GBP
- Clinical Trials
- April 2025
- 180 Pages
Global
From €2221EUR$2,500USD£1,935GBP
- Clinical Trials
- April 2025
- 100 Pages
Global
From €1777EUR$2,000USD£1,548GBP
- Report
- May 2025
- 73 Pages
Global
From €3500EUR$4,221USD£3,156GBP
- Report
- October 2025
- 89 Pages
Qatar
From €4308EUR$4,850USD£3,753GBP
- Report
- July 2025
- 90 Pages
Japan
From €4930EUR$5,550USD£4,295GBP

The GLP-1 Receptor Agonist market is a subset of the Central Nervous System Drugs market. GLP-1 Receptor Agonists are drugs that act on the GLP-1 receptor, a protein found in the brain and other parts of the body. These drugs are used to treat a variety of conditions, including obesity, type 2 diabetes, and depression. GLP-1 Receptor Agonists work by stimulating the release of insulin and other hormones, which can help regulate blood sugar levels and reduce appetite.
GLP-1 Receptor Agonists are typically administered as injections, and are often used in combination with other medications. They are generally well-tolerated, with few side effects. However, they can be expensive, and may not be covered by insurance.
Some companies in the GLP-1 Receptor Agonist market include Novo Nordisk, Eli Lilly, AstraZeneca, and Sanofi. Show Less Read more